Transcutaneous delivery of CpG-adjuvanted allergen via laser-generated micropores

Vaccine

Volumn 31, Issue 34, 2013, Pages 3427-3434

  Hessenberger, Michael ^a   Weiss, Richard ^a   Weinberger, Esther E ^a   Boehler, Christof ^b   Thalhamer, Josef ^a   Scheiblhofer, Sandra ^a  

^a UNIVERSITY OF SALZBURG   (Austria)

^b Pantec Biosolutions AG   (Liechtenstein)

Author keywords

CpG oligodeoxynucleotides; Immunotherapy; Laser microporation; Skin immunization; Transcutaneous; Type I allergy

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PH1 P 5 ALLERGEN; POLLEN ANTIGEN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOTHERAPY; LASER MICRODISSECTION; LASER MICROPORATION; LUNG LAVAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; TRANSCUTANEOUS IMMUNOTHERAPY;

ALLERGEN-SPECIFIC IMMUNOTHERAPY; BAL; BALF; BRONCHOALVEOLAR LAVAGE; BRONCHOALVEOLAR LAVAGE FLUID; CPG OLIGODEOXYNUCLEOTIDES; IMMUNOTHERAPY; LASER MICROPORATION; P.L.E.A.S.E.(®); PRECISE LASER EPIDERMAL SYSTEM; SCIT; SIT; SKIN IMMUNIZATION; SLIT; SUBCUTANEOUS ALLERGEN-SPECIFIC IMMUNOTHERAPY; SUBLINGUAL ALLERGEN-SPECIFIC IMMUNOTHERAPY; T HELPER; TCI; TCIT; TH; TRANSCUTANEOUS; TRANSCUTANEOUS ALLERGEN-SPECIFIC IMMUNOTHERAPY; TRANSCUTANEOUS IMMUNIZATION; TYPE I ALLERGY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ALLERGENS; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; EOSINOPHILS; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INFLAMMATION; LASERS; LYMPHOCYTES; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; POACEAE; POLLEN; TRANSDERMAL PATCH;

EID: 84880508240     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.09.086     Document Type: Article

References (44)

1. Maggi E., Vultaggio A., Matucci A. T-cell responses during allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol 2012, 12(February (1)):1-6.
2. Akdis C.A., Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2011, 127(January (1)):8-9. [18-27; quiz].
3. Eifan A.O., Shamji M.H., Durham S.R. Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol 2011, 11(December (6)):586-593.
4. Jacobsen L., Niggemann B., Dreborg S., Ferdousi H.A., Halken S., Host A., et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007, 62(August (8)):943-948.
5. Cox L., Calderon M.A. Subcutaneous specific immunotherapy for seasonal allergic rhinitis: a review of treatment practices in the US and Europe. Curr Med Res Opin 2010, 26(December (12)):2723-2733.
6. Werfel T. Epicutaneous allergen administration: a novel approach for allergen-specific immunotherapy?. J Allergy Clin Immunol 2009, 124(November (5)):1003-1004.
7. More D.R., Hagan L.L. Factors affecting compliance with allergen immunotherapy at a military medical center. Ann Allergy Asthma Immunol 2002, 88(April (4)):391-394.
8. Senna G., Lombardi C., Canonica G.W., Passalacqua G. How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. J Allergy Clin Immunol 2010, 126(September (3)):668-669.
9. Frew A.J., Sublingual immunotherapy. N Engl J Med 2008, 358(May (21)):2259-2264.
10. Frew A.J., Allergen immunotherapy. J Allergy Clin Immunol 2010, 125(February (2 Suppl. 2)):S306-S313.
11. Bachhav Y.G., Heinrich A., Kalia Y.N. Using laser microporation to improve transdermal delivery of diclofenac: increasing bioavailability and the range of therapeutic applications. Eur J Pharm Biopharm 2011, 78(August (3)):408-414.
12. Bachhav Y.G., Summer S., Heinrich A., Bragagna T., Bohler C., Kalia Y.N. Effect of controlled laser microporation on drug transport kinetics into and across the skin. J Control Release 2010, 146(August (1)):31-36.
13. Yu J., Bachhav Y.G., Summer S., Heinrich A., Bragagna T., Bohler C., et al. Using controlled laser-microporation to increase transdermal delivery of prednisone. J Control Release 2010, 148(November (1)):e71-e73.
14. Yu J., Kalaria D.R., Kalia Y.N., Erbium: YAG fractional laser ablation for the percutaneous delivery of intact functional therapeutic antibodies. J Control Release 2011, 156(November (1)):53-59.
15. Blamoutier P., Blamoutier J., Guibert L. Traitement de la pollinose avec extraits de pollens par la méthode des quadrillages cutanés. Presse Med 1959, 67(December):2299-2301.
16. Senti G., Graf N., Haug S., Ruedi N., von Moos S., Sonderegger T., et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol 2009, 124(November (5)):997-1002.
17. Senti G., von Moos S., Tay F., Graf N., Sonderegger T., Johansen P., et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol 2012, 129(January (1)):128-135.
18. Dupont C., Kalach N., Soulaines P., Legoue-Morillon S., Piloquet H., Benhamou P.H. Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol 2010, 125(May (5)):1165-1167.
19. Mondoulet L., Dioszeghy V., Ligouis M., Dhelft V., Dupont C., Benhamou P.H. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin Exp Allergy 2010, 40(April (4)):659-667.
20. Strid J., Callard R., Strobel S. Epicutaneous immunization converts subsequent and established antigen-specific T helper type 1 (Th1) to Th2-type responses. Immunology 2006, 119(September (1)):27-35.
21. Strid J., Hourihane J., Kimber I., Callard R., Strobel S. Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 response. Eur J Immunol 2004, 34(August (8)):2100-2109.
22. He R., Kim H.Y., Yoon J., Oyoshi M.K., MacGinnitie A., Goya S., et al. Exaggerated IL-17 response to epicutaneous sensitization mediates airway inflammation in the absence of IL-4 and IL-13. J Allergy Clin Immunol 2009, 124(October (4)):761-770.e1.
23. Strid J., Hourihane J., Kimber I., Callard R., Strobel S. Epicutaneous exposure to peanut protein prevents oral tolerance and enhances allergic sensitization. Clin Exp Allergy 2005, 35(June (6)):757-766.
24. Weiss R., Hessenberger M., Kitzmuller S., Bach D., Weinberger E.E., Krautgartner W.D., et al. Transcutaneous vaccination via laser microporation. J Control Release 2012, 162(September (2)):391-399.
25. Guebre-Xabier M., Hammond S.A., Epperson D.E., Yu J., Ellingsworth L., Glenn G.M. Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells. J Virol 2003, 77(May (9)):5218-5225.
26. Bode C., Zhao G., Steinhagen F., Kinjo T., Klinman D.M. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2011, 10(April (4)):499-511.
27. Hartl A., Weiss R., Hochreiter R., Scheiblhofer S., Thalhamer J. DNA vaccines for allergy treatment. Methods 2004, 32(March (3)):328-339.
28. Gabler M., Scheiblhofer S., Kern K., Leitner W.W., Stoecklinger A., Hauser-Kronberger C., et al. Immunization with a low-dose replicon DNA vaccine encoding Phl p 5 effectively prevents allergic sensitization. J Allergy Clin Immunol 2006, 118(September (3)):734-741.
29. Strid J., Sobolev O., Zafirova B., Polic B., Hayday A. The intraepithelial T cell response to NKG2D-ligands links lymphoid stress surveillance to atopy. Science 2011, 334(December (6060)):1293-1297.
30. Ebner S., Nguyen V.A., Forstner M., Wang Y.H., Wolfram D., Liu Y.J., et al. Thymic stromal lymphopoietin converts human epidermal Langerhans cells into antigen-presenting cells that induce proallergic T cells. J Allergy Clin Immunol 2007, 119(April (4)):982-990.
31. Soumelis V., Reche P.A., Kanzler H., Yuan W., Edward G., Homey B., et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 2002, 3(July (7)):673-680.
32. Beignon A.S., Briand J.P., Muller S., Partidos C.D. Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells. Immunology 2002, 105(February (2)):204-212.
33. Besnard A.G., Sabat R., Dumoutier L., Renauld J.C., Willart M., Lambrecht B., et al. Dual role of IL-22 in allergic airway inflammation and its cross-talk with IL-17A. Am J Respir Crit Care Med 2011, 183(May (9)):1153-1163.
34. Nakagome K., Imamura M., Kawahata K., Harada H., Okunishi K., Matsumoto T., et al. High expression of IL-22 suppresses antigen-induced immune responses and eosinophilic airway inflammation via an IL-10-associated mechanism. J Immunol 2011, 187(November (10)):5077-5089.
35. Besnard A.G., Togbe D., Couillin I., Tan Z., Zheng S.G., Erard F., et al. Inflammasome-IL-1-Th17 response in allergic lung inflammation. J Mol Cell Biol 2012, 4(February (1)):3-10.
36. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6(November (11)):1123-1132.
37. Haapakoski R., Karisola P., Fyhrquist N., Savinko T., Wolff H., Turjanmaa K., et al. Intradermal cytosine-phosphate-guanosine treatment reduces lung inflammation but induces IFN-gamma-mediated airway hyperreactivity in a murine model of natural rubber latex allergy. Am J Respir Cell Mol Biol 2011, 44(May (5)):639-647.
38. Duechs M.J., Hahn C., Benediktus E., Werner-Klein M., Braun A., Hoymann H.G., et al. TLR agonist mediated suppression of allergic responses is associated with increased innate inflammation in the airways. Pulm Pharmacol Ther 2011, 24(April (2)):203-214.
39. Clark R.A. Skin-resident T cells: the ups and downs of on site immunity. J Invest Dermatol 2010, 130(February (2)):362-370.
40. Bal S.M., Ding Z., van Riet E., Jiskoot W., Bouwstra J.A. Advances in transcutaneous vaccine delivery: do all ways lead to Rome?. J Control Release 2010, 148(December (3)):266-282.
41. Mestas J., Hughes C.C. Of mice and not men: differences between mouse and human immunology. J Immunol 2004, 172(March (5)):2731-2738.
42. Guilliams M., Henri S., Tamoutounour S., Ardouin L., Schwartz-Cornil I., Dalod M., et al. From skin dendritic cells to a simplified classification of human and mouse dendritic cell subsets. Eur J Immunol 2010, 40(August (8)):2089-2094.
43. Bach D., Weiss R., Hessenberger M., Kitzmueller S., Weinberger E.E., Krautgartner W.D., et al. Transcutaneous immunotherapy via laser-generated micropores efficiently alleviates allergic asthma in Phl p 5-sensitized mice. Allergy 2012, 67(November (11)):1365-1374.
44. Senti G., Johansen P., Haug S., Bull C., Gottschaller C., Muller P., et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy 2009, 39(April (4)):562-570.